Effect of MSPrebiotic on Gastrointestinal Function and Blood Glucose Levels

Gastrointestinal Function Clinical Trial

Official title:

Effect of MSPrebiotic Digestion Resistant Starch on Gastrointestinal Function and Blood Glucose Levels

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03910153
• Other study ID #: MSPCT2
• Status: Completed
• Phase: N/A
• Start date: April 8, 2019
• Est. completion date: October 7, 2019

Study information

• Verified date: January 2022
• Source: Manitoba Starch Products
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to investigate the impact of daily consumption of MSPrebiotic at a dosage level of 30 g per day for 12 weeks on gastrointestinal microbiota in the elderly (> 70 years age) and another age group (30 to 50 years). In addition, impact of MSPrebiotic on short chain fatty acids, glucose and insulin levels as well as metabolomic changes will also be studied. A randomized, double-blinded study will be conducted to assess the health benefits of MSPrebiotic and compared with a placebo. This study will provide substantiation for a beneficial effect of MSPrebiotic resistant starch on gut microbiome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: October 7, 2019
• Est. primary completion date: October 7, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Ability to provide written informed consent (or by the authorized 3rd party).

• Willing to provide stool (2 times) and blood (6 times) samples over the 14 week study period

• Subjects between 30-50 and above 70 years of age

• Subjects willing to provide fasting blood during Screening and weeks 0, 2, 6, 10 and 14 visits

• Female subjects not pregnant or breast feeding

• Female subjects not planning for pregnancy during the study period

Exclusion Criteria:

• Crohn's disease or any other inflammatory bowel disease

• Individuals with Lupus, or on cancer chemotherapy

• Pre-diabetes or Diabetes

• Thyroid disease

• Renal disease

• Hepatic disease

• Previous gastrointestinal surgery (intestinal resection, gastric bypass, colorectal surgery)

• Subjects on probiotic (e.g. yoghurt),

• Subjects on antibiotics at time of recruitment or on antibiotics within the previous five weeks

• Individuals experiencing dysphagia

• Subjects using additional fiber supplements

• Subjects on digestants, emetics and antiemetics, medications for acid peptic disease and antacids.

• Subjects allergic to potato or corn

• Have conditions, factors, medication (other than those listed above) that the Investigator believes may affect the response of the gut or the interpretation of the test results

Related Conditions & MeSH terms

• Gastrointestinal Function

Intervention

Dietary Supplement:
• MSPrebiotic
MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.

Other:
• Placebo
Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.

Locations

Country	Name	City	State
Canada	Hill Top Research	Winnipeg	Manitoba

Sponsors (2)

Lead Sponsor	Collaborator
Manitoba Starch Products	Source Nutraceutical, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes from baseline in gut microbiome	Gut microbiome composition (ratio between number of Firmicutes and Bacteroides) will be measured using 16S ribosomal ribonucleic acid (rRNA) gene sequencing in stool samples	0 and 14 weeks
Primary	Changes from baseline in concentration of short chain fatty acids in stool samples	Concentration of short chain fatty acids (acetate, propionate, butyrate, isobutyrate, valerate,isovalerate) in feces will be measured using gas chromatographic method	0 and 14 weeks
Primary	Changes from baseline in bowel movements with respect to number of bowel movements and stool consistency	Number of bowel movements will be measured using questionnaire. Stool consistency will be measured using questionnaires recording Bristol score. Bristol stool chart indicates the following types: Type 1-Separate hard lumps, like nuts; Type 2-Sausage-shaped but lumpy; Type 3-Like a sausage but with cracks on its surface; Type 4-Like a sausage or snake, smooth and soft; Type 5-Soft blobs with clear-cut edges (passed easily); Type 6-Fluffy pieces with ragged edges, a mushy stool; Type 7-Watery, no solid pieces. Entirely liquid.	0, 2, 6,10 and 14 weeks
Primary	Changes from baseline in blood glucose concentrations	Blood glucose levels concentrations will be measured using standard laboratory methods	0, 2, 6,10 and 14 weeks
Primary	Changes from baseline in blood insulin concentrations	Blood insulin concentrations will be measured using standard laboratory methods	0 and 14 weeks
Secondary	Changes from baseline in tolerability in terms of excessive flatulence, abdominal pain, and bloating: questionnaires	Tolerability of consuming MSPrebiotic in terms of excessive flatulence, abdominal pain, and bloating will be measured using questionnaires. The questionnaire will record the severity of flatulence, abdominal pain and bloating on a scale of 1 to 5 where 1=none and 5=extreme.	0, 2, 6,10 and 14 weeks
Secondary	Changes from baseline in overall health in terms of outpatient visits and hospitalizations	Overall health will be measured using questionnaires on outpatient visits and hospitalizations. The questionnaire contains Yes/No question to record if the subject had any outpatient visits or hospitalizations.	0, 2, 6,10 and 14 weeks
Secondary	Changes from baseline in concentration of blood lipids and C-reactive protein Inflammatory marker C-reactive protein. Metabolomic changes	Concentration of blood lipids and C-reactive protein will be measured using standard laboratory methods.	0 and14 weeks
Secondary	Changes from baseline in concentration of blood and fecal Metabolomics	Concentration of blood and fecal metabolomics will be measured using reverse phase liquid chromatography quadrupole time of flight tandem mass spectroscopy (RPLC-QTOF-MS/MS)	0 and 14 weeks